Trevena, Inc. is a biopharmaceutical company that develops medicines for patients with central nervous system disorders. Its lead product candidates include drugs for pain management, acute respiratory distress, abnormal blood clotting, and migraine treatment. The company also collaborates with Imperial College London to evaluate the effectiveness of its drug, TRV027, in treating COVID-19 patients.